Slideshow

Lupus Trial for Anifrolumab Gets a Second Look

Anifrolumab, a potential new treatment for systemic lupus erythematosus (SLE), was given a second look in a clinical trial published in the New England Journal of Medicine this month. This time, the results look promising. Learn more about the trial in this slideshow.

Anifrolumab, a potential new treatment for systemic lupus erythematosus (SLE), was given a second look in a clinical trial published in the New England Journal of Medicine this month. This time, the results look promising. Learn more about the trial in this slideshow.RELATED:  Anifrolumab Shows Efficiency in Systemic LupusREFERENCE:  Eric F. Morand, M.B., B.S., Ph.D.; Richard Furie, M.D., Yoshiya Tanaka, M.D., Ph.D., et al. "Trial of Anifrolumab in Active Systemic Lupus Erythematosus," NEJM. Jan. 16, 2020. DOI: 10.1056/NEJMoa1912196 

Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
© 2025 MJH Life Sciences

All rights reserved.